ICD-10 Support

ICD-10 Support

The ICD-10 Diagnosis Codes For Providers

Easy access to the information you may need

If you’re a provider, you’ll want to get familiar with billing codes that went into effect October 1, 2015. While sample ICD-9-CM codes have been mapped to the latest ICD-10-CM codes so that coders can become familiar with the new codes, the ultimate responsibility for correct coding lies with the provider of services. The codes included in the charts below are not intended to be promotional, or to encourage or suggest a use of any drug that is inconsistent with FDA-approved use.

Please refer to the current policy for the latest codes since these codes are subject to change. The codes provided are not intended to be exhaustive. Please consult your ICD-10 code book for additional information.

Click below for an ICD-10 Crosswalk Sample.

DIABETES MELLITUS

ICD-9 Indication ICD-9 Code ICD-10 Indication ICD-10 Code
DIABETES MELLITUS 250.00-250.93 DIABETES MELLITUS E11-E13.9*
  *Use additional code to identify any insulin use (Z79.4)
The following fifth-digit subclassification is for use with category 250:
... 0 or type II unspecified type, not stated as uncontrolled, Fifth-digit 0 is for use with type II patients, even if the patient requires insulin
  Type 2 diabetes mellitus
Includes:
... Diabetes (mellitus) due to insulin secretory defect
... Diabetes NOS
... Insulin resistant diabetes (mellitus)
E11.XX
Use additional code, if applicable, for associated
long-term (current) insulin use V58.67
 
... 1 type I [juvenile type], not stated as uncontrolled    
... 2 type II or unspecified type, uncontrolled    
... Fifth-digit 2 is for use with type II patients, even if the patient requires insulin    
Use additional code, if applicable, for associated long-term (current) insulin use V58.67    
... 3 type I [juvenile type], uncontrolled    
Diabetes (mellitus) without mention of complication [0-3] 250.0X Type 2 diabetes mellitus without complications E11.9
... Diabetes (mellitus) NOS   Other specified diabetes mellitus without complication E13.9
Diabetes with hyperosmolarity [0-3]
... Hyperosmolar (nonketotic coma)
250.2X Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) E11.00
    Type 2 diabetes mellitus with hyperosmolarity with coma E11.01
    Other specified diabetes mellitus E13.XX
    ... with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) E13.00
    ... with hyperosmolarity with coma E13.01
Diabetes with renal manifestations [0-3] 250.4X* Type 2 diabetes mellitus with diabetic nephropathy E11.21
*Use additional code to identify manifestation.
Please refer to ICD-9 book for manifestation codes
Type 2 diabetes mellitus with diabetic chronic kidney disease E11.22*
    *Use additional code to identify stage of chronic kidney disease (N18.1-N18.6)
    Type 2 diabetes mellitus with other diabetic kidney complication E11.29
    Other specified diabetes mellitus with diabetic nephropathy E13.21
    Other specified diabetes mellitus with diabetic chronic kidney disease E13.22*
    *Use additional code to identify stage of chronic kidney disease (N18.1-N18.6)
    Other specified diabetes mellitus with other diabetic kidney complication E13.29
Diabetes with ophthalmic manifestations [0-3] 250.5X* Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema E11.311
*Use additional code to identify manifestation.
Please refer to ICD-9 book for manifestation codes
Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema E11.319
    Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema E11.321
    Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema E11.329
    Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema E11.331
    Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema E11.339
    Type 2 diabetes with severe nonproliferative diabetic retinopathy with macular edema E11.341
    Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema E11.349
    Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema E11.351
    Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula E11.352
    Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula E11.353
    Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment E11.354
    Type 2 diabetes mellitus with stable proliferative diabetic retinopathy E11.355
    Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema E11.359
    Type 2 diabetes mellitus with diabetic cataract E11.36
    Type 2 diabetes mellitus with diabetic mascular edema, resolved following treatment E11.37
    Type 2 diabetes mellitus with other diabetic ophthalmic complication E11.39*
  *Use additional code to identify manifestation, such as: diabetic glaucoma (H40-H42)
    Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema E13.311
    Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema E13.319
    Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema E13.321
    Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema E13.329
    Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema E13.331
    Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema E13.339
    Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema E13.341
    Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema E13.349
    Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema E13.351
    Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula E13.352
    Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula E13.353
    Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment E13.354
    Other specified diabetes mellitus with stable proliferative diabetic retinopathy E13.355
    Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema E13.359
    Other specified diabetes mellitus with diabetic cataract E13.36
    Other specified diabetes mellitus with diabetic macular edema, resolved following treatment E13.37
    Other specified diabetes mellitus with other diabetic ophthalmic complication E13.39*
  *Use additional code to identify manifestation, such as: diabetic glaucoma (H40-H42)
DIABETES MELLITUS 250.00-250.93 DIABETES MELLITUS E11-E13.9*
  *Use additional code to identify any insulin use (Z79.4)
Diabetes with neurological manifestations [0-3] 250.6X* Type 2 diabetes mellitus with diabetic neuropathy, unspecified E11.40
*Use additional code to identify manifestation.
Please refer to ICD-9 book for manifestation codes
Type 2 diabetes mellitus with diabetic mononeuropathy E11.41
    Type 2 diabetes mellitus with diabetic polyneuropathy E11.42
    Type 2 diabetes mellitus with diabetic autonomic (poly) neuropathy E11.43
    Type 2 diabetes mellitus with diabetic amyotrophy E11.44
    Type 2 diabetes mellitus with other diabetic neurological complication E11.49
    Type 2 diabetes mellitus with diabetic neuropathic arthropathy E11.610
    Other specified diabetes mellitus with diabetic neuropathy, unspecified E13.40
    Other specified diabetes mellitus with diabetic mononeuropathy E13.41
    Other specified diabetes mellitus with diabetic polyneuropathy E13.42
    Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy E13.43
    Other specified diabetes mellitus with diabetic amyotrophy E13.44
    Other specified diabetes mellitus with diabetic neurological complication E13.49
    Other specified diabetes mellitus with diabetic neuropathic arthropathy E13.610
Diabetes with peripheral circulatory disorders [0-3] 250.7X* Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene E11.51
*Use additional code to identify manifestation.
Please refer to ICD-9 book for manifestation codes
Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene E11.52
    Type 2 diabetes mellitus with other circulatory complications E11.59
    Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene E13.51
    Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene E13.52
    Other specified diabetes mellitus with other circulatory complications E13.59
Diabetes with other specified manifestations [0-3] 250.8X* Type 2 diabetes mellitus with other diabetic arthropathy E11.618
    Type 2 diabetes mellitus with diabetic dermatitis E11.620
*Use additional code to identify manifestation.
Please refer to ICD-9 book for manifestation codes
Type 2 diabetes mellitus with foot ulcer E11.621*
    *Use additional code to identify site of ulcer (L97.4-, L97.5-)
    Type 2 diabetes mellitus with other skin ulcer E11.622*
    *Use additional code to identify site of ulcer (L97.1-L97.9, L98.41-L98.49)
    Type 2 diabetes mellitus with other skin complications E11.628
    Type 2 diabetes mellitus with periodontal disease E11.630
    Type 2 diabetes mellitus with other oral complications E11.638
    Type 2 diabetes mellitus with hypoglycemia without coma E11.649
    Type 2 diabetes mellitus with hyperglycemia E11.65
    Type 2 diabetes mellitus with other specified complication E11.69*
    *Use additional code to identify complication
    Other specified diabetes mellitus with diabetic dermatitis E13.620
    Other specified diabetes mellitus with foot ulcer E13.621*
    *Use additional code to identify site of ulcer (L97.4-, L97.5)
    Other specified diabetes mellitus with other skin ulcer E13.622*
    *Use additional code to identify site of ulcer (L97.1-L97.9, L98.41-L98.49)
    Other specified diabetes mellitus with other skin complications E13.628
    Other specified diabetes mellitus with periodontal disease E13.630
    Other specified diabetes mellitus with other oral complications E13.638
    Other specified diabetes mellitus with hypoglycemia without coma E13.649
    Other specified diabetes mellitus with hyperglycemia E13.65
    Other specified diabetes mellitus with other specified complication E13.69*
    *Use additional code to identify complication
Diabetes with unspecified complication [0-3] 250.9X Type 2 diabetes mellitus with unspecified complications E11.8
    Other specified diabetes mellitus with unspecified complications E13.8

For more information on the transition to ICD-10, visit the CMS Web site.

SOURCE:
American Medical Association. ICD10-CM 2017: The Complete Official Codebook. 2016. American Medical Association.

THE INFORMATION CONTAINED IN THIS DOCUMENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND REPRESENTS NO STATEMENT, PROMISE, OR GUARANTEE BY JANSSEN PHARMACEUTICALS, INC. CONCERNING LEVELS OF REIMBURSEMENT, PAYMENT, OR CHARGE. SIMILARLY, ALL CPT® (©AMA) AND HCPCS CODES ARE SUPPLIED FOR INFORMATIONAL PURPOSES ONLY AND REPRESENT NO STATEMENT, PROMISE, OR GUARANTEE BY JANSSEN PHARMACEUTICALS, INC. THAT THESE CODES WILL BE APPROPRIATE OR THAT REIMBURSEMENT WILL BE MADE. IT IS NOT INTENDED TO INCREASE OR MAXIMIZE REIMBURSEMENT BY ANY PAYER. WE STRONGLY RECOMMEND THAT YOU CONSULT YOUR PAYER ORGANIZATION WITH REGARD TO ITS REIMBURSEMENT POLICIES.

INDICATION AND USAGE

INVOKANA® (canagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

INVOKANA® is not recommended in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Important Safety Information For INVOKANA®

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • History of a serious hypersensitivity reaction to INVOKANA®, such as anaphylaxis or angioedema
  • Severe renal impairment (eGFR <30 mL/min/1.73 m2 ), end-stage renal disease, or patients on dialysis

WARNINGS and PRECAUTIONS

  • Hypotension: INVOKANA® causes intravascular volume contraction. Symptomatic hypotension can occur after initiating INVOKANA®, particularly in patients with impaired renal function (eGFR <60 mL/min/1.73 m2 ), elderly patients, patients on either diuretics or medications that interfere with the renin-angiotensin-aldosterone system, or patients with low systolic blood pressure. Before initiating in patients with ≥1 of these characteristics, volume status should be assessed and corrected. Monitor for signs and symptoms after initiating.
  • Ketoacidosis: Reports of ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, have been identified in patients with type 1 and 2 diabetes mellitus receiving SGLT2 inhibitors, including INVOKANA®. Fatal cases of ketoacidosis have been reported in patients taking INVOKANA®. Before initiating INVOKANA®, consider factors in patient history that may predispose to ketoacidosis, including pancreatic insulin deficiency, caloric restriction disorders, and alcohol abuse. In patients treated with INVOKANA®, consider monitoring for ketoacidosis and temporarily discontinuing in clinical situations known to predispose to ketoacidosis (eg, prolonged fasting due to acute illness or surgery).
  • Acute Kidney Injury and Impairment in Renal Function: INVOKANA® causes intravascular volume contraction and can cause renal impairment. Postmarketing reports of acute kidney injury, some requiring hospitalization and dialysis, were reported; some reports involved patients younger than 65 years of age. Before initiation, consider factors that may predispose patients to acute kidney injury including hypovolemia, chronic renal insufficiency, congestive heart failure and concomitant medications. Consider temporarily discontinuing INVOKANA® in any setting of reduced oral intake or fluid losses; monitor patients for signs and symptoms of acute kidney injury. If acute kidney injury occurs, discontinue promptly and institute treatment.

    INVOKANA® increases serum creatinine and decreases eGFR. Patients with hypovolemia may be more susceptible to these changes. Renal function abnormalities can occur after initiation. Renal function should be evaluated prior to initiation and periodically thereafter. Dose adjustment and more frequent renal function monitoring are recommended in patients with an eGFR <60 mL/min/1.73 m2.

  • Hyperkalemia: INVOKANA® can lead to hyperkalemia. Patients with moderate renal impairment who are taking medications that interfere with potassium excretion or medications that interfere with the renin-angiotensin-aldosterone system are more likely to develop hyperkalemia. Monitor serum potassium levels periodically in patients with impaired renal function and in patients predisposed to hyperkalemia due to medications or other medical conditions.
  • Urosepsis and Pyelonephritis: There have been reports of serious urinary tract infections, including urosepsis and pyelonephritis, requiring hospitalization in patients receiving SGLT2 inhibitors, including INVOKANA®. Treatment with SGLT2 inhibitors increases this risk. Evaluate patients for signs and symptoms and treat promptly.
  • Hypoglycemia With Concomitant Use With Insulin and Insulin Secretagogues: INVOKANA® can increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue. A lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with INVOKANA®.
  • Genital Mycotic Infections: INVOKANA® increases risk of genital mycotic infections. Patients with history of these infections and uncircumcised males were more likely to develop these infections. Monitor and treat appropriately.
  • Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema and anaphylaxis, were reported with INVOKANA®; these reactions generally occurred within hours to days after initiation. If reactions occur, discontinue INVOKANA®, treat per standard of care, and monitor until signs and symptoms resolve.
  • Bone Fracture: Increased risk of bone fracture, occurring as early as 12 weeks after treatment initiation, was observed in patients using INVOKANA®. Consider factors that contribute to fracture risk prior to initiating INVOKANA®.
  • Increases in Low-Density Lipoprotein (LDL-C): Dose-related increases in LDL-C can occur with INVOKANA®. Monitor LDL-C and treat per standard of care after initiating.
  • Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with INVOKANA®.

DRUG INTERACTIONS

  • UGT Enzyme Inducers: Rifampin: Co-administration of INVOKANA® with rifampin decreased INVOKANA® area under the curve (AUC) by 51% and therefore may decrease efficacy. If an inducer of UGT enzymes must be co-administered with INVOKANA®, consider increasing the dose to 300 mg once daily if patients are currently tolerating INVOKANA® 100 mg once daily, have an eGFR ≥60 mL/min/1.73 m2 , and require additional glycemic control. Consider other antihyperglycemic therapy in patients with an eGFR <60 mL/min/1.73 m2  who require additional glycemic control.
  • Digoxin: There was an increase in the AUC and mean peak drug concentration of digoxin (20% and 36%, respectively) when co-administered with INVOKANA® 300 mg. Monitor appropriately.
  • Positive Urine Glucose Test: Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose test results. Use alternative methods to monitor glycemic control.
  • Interference With 1,5-Anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: Based on animal data showing adverse renal effects, INVOKANA® is not recommended during the second and third trimesters of pregnancy. Limited data with INVOKANA® in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are risks to mother and fetus associated with poorly controlled diabetes in pregnancy.
  • Nursing Mothers: There is no information regarding the presence of INVOKANA® in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed infant, advise women that use of INVOKANA® is not recommended while breastfeeding.
  • Pediatric Use: Safety and effectiveness in patients <18 years of age have not been established.
  • Geriatric Use: 2034 patients ≥65 years and 345 patients ≥75 years were exposed to INVOKANA® in 9 clinical studies. Patients ≥65 years had a higher incidence of adverse reactions related to reduced intravascular volume (eg, hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration), particularly with the 300-mg dose, compared to younger patients; more prominent increase in the incidence was seen in patients who were ≥75 years. Smaller reductions in HbA1c relative to placebo were seen in patients ≥65 years (-0.61% with INVOKANA® 100 mg and -0.74% with INVOKANA® 300 mg) compared to younger patients (-0.72% with INVOKANA® 100 mg and -0.87% with INVOKANA® 300 mg).
  • Renal Impairment: Efficacy and safety were evaluated in a study that included patients with moderate renal impairment (eGFR 30 to <50 mL/min/1.73 m2). These patients had less overall glycemic efficacy and a higher occurrence of adverse reactions related to reduced intravascular volume, renal-related adverse reactions, and decreases in eGFR compared to patients with mild renal impairment or normal renal function (eGFR ≥60 mL/min/1.73 m2 ); patients treated with 300 mg were more likely to experience increases in potassium. INVOKANA® is not recommended in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2 ), with end-stage renal disease, or receiving dialysis.
  • Hepatic Impairment: INVOKANA® has not been studied in patients with severe hepatic impairment and is not recommended in this population.

OVERDOSAGE

  • In the event of an overdose, contact the Poison Control Center and employ the usual supportive measures, eg, remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment as needed.

ADVERSE REACTIONS

  • The most common adverse reactions associated with INVOKANA® (5% or greater incidence) were female genital mycotic infections, urinary tract infections, and increased urination.

Please see full Prescribing Information and Medication Guide.

066709-170206